Screener
Alnylam Pharmaceuticals ALNY Royalty revenue — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Net product revenues | $1,172,109 | $672,212 | $2,208,236 | $1,140,750 |
| Net revenues from collaborations | 47,165 | 61,496 | 129,240 | 160,681 |
| Royalty revenue | 71,674 | 39,981 | 120,647 | 66,447 |
| Total revenues | 1,290,948 | 773,689 | 2,458,123 | 1,367,878 |
| Operating costs and expenses: | ||||
| Cost of goods sold | 298,261 | 142,029 | 505,781 | 212,212 |
| Cost of collaborations and royalties | 190 | 924 | 3,792 | 1,782 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's royalty revenue — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported royalty revenue — total revenues of $71.67M in Q2 2026.
- How has Alnylam Pharmaceuticals's royalty revenue — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's royalty revenue — total revenues increased by 79.3% year-over-year, from $39.98M to $71.67M.
- What is the long-term trend for Alnylam Pharmaceuticals's royalty revenue — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's royalty revenue — total revenues has grown at a 247.3% compound annual growth rate (CAGR), from $1.2M to $174.02M.
- What does royalty revenue — total revenues mean?
- This metric represents the total revenue generated from royalty payments earned through licensing intellectual property or therapeutic assets to third-party partners. It reflects the company's ability to monetize its research and development pipeline by allowing external entities to commercialize its proprietary technology in exchange for a percentage of net sales. Growth in this segment indicates successful long-term strategic partnerships and the market adoption of licensed therapies.
Ask your AI about Alnylam Pharmaceuticals's royalty revenue — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude